轮状病毒疫苗接种对肯尼亚中部全因及轮状病毒特异性胃肠炎和毒株分布的长期影响:一项11年中断时间序列分析
该研究基于肯尼亚中部一家医院2009至2020年11年<5岁儿童急性胃肠炎监测数据,比较疫苗接种前、早期和晚期后轮状病毒特异性及全因急性胃肠炎住院变化。结果显示,与接种前相比,轮状病毒特异性急性胃肠炎在早期和晚期分别下降49.8%和53.4%,全因急性胃肠炎住院分别下降40.2%和75.3%;晚期优势株由G1P[8]变为G3P[8],并检出一定比例不常见株G3P[6]和G12P[6]。
要点
- 与接种前相比,轮状病毒特异性急性胃肠炎早期下降49.8%,晚期下降53.4%。
- 与接种前相比,全因急性胃肠炎住院早期下降40.2%,晚期下降75.3%。
- 晚期优势株由G1P[8]变为G3P[8],并检出G3P[6](4.8%)和G12P[6](3.5%)。
核心结论
- 轮状病毒疫苗接种导致全因和轮状病毒特异性急性胃肠炎显著下降,为肯尼亚公共卫生政策制定者支持在常规免疫中持续使用轮状病毒疫苗提供了有力证据。
- 疫苗接种后时代毒株优势度和轮状病毒急性胃肠炎年龄分布的变化,强调需要持续监测以评估任何可能的疫苗诱导选择压力,这种压力可能随时间推移降低疫苗效果。
研究设计与样本
- 研究为基于医院的11年监测分析,数据来自肯尼亚中部Kiambu县教学和转诊医院(KCTRH)2009年至2020年<5岁儿童急性胃肠炎监测。
- 粪便样本使用ELISA筛查A组轮状病毒,并使用多重半巢式RT-PCR进行基因分型。
- 比较疫苗接种前(2009年7月-2014年6月)、疫苗接种后早期(2014年7月-2016年6月)和疫苗接种后晚期(2019年2月-2020年10月)三个时期的趋势。
主要发现
- 轮状病毒特异性急性胃肠炎检出率在疫苗接种前为27.5%(429/1546,95%CI:25.5-30.1%),疫苗接种后早期为13.8%(91/658,95%CI:11.3-16.6%),疫苗接种后晚期为12.0%(229/1916,95%CI:10.6-13.5%)。
- 与疫苗接种前相比,轮状病毒特异性急性胃肠炎在疫苗接种后早期下降49.8%(95%CI:34.6%-63.7%),在疫苗接种后晚期下降53.4%(95%CI:41.5-70.3%)。
- 与疫苗接种前相比,全因急性胃肠炎住院在疫苗接种后早期下降40.2%(95%CI:30.8%-50.2%),在疫苗接种后晚期下降75.3%(95%CI:65.9-83.1%)。
- G3P[8]是疫苗接种后晚期的优势株,取代了在疫苗接种前和疫苗接种后早期占优势的G1P[8]。
- 在疫苗接种后时代检出相当比例的不常见株G3P[6](4.8%)和G12P[6](3.5%)。
临床怎么用
- 作者认为,轮状病毒疫苗接种导致全因和轮状病毒特异性急性胃肠炎显著下降,为肯尼亚公共卫生政策制定者支持在常规免疫中持续使用轮状病毒疫苗提供了有力证据。
- 作者指出,疫苗接种后时代毒株优势度和年龄分布的变化强调需要持续监测以评估任何可能的疫苗诱导选择压力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Kenya introduced a monovalent rotavirus vaccine administered orally at 6 and 10 weeks of age into her National Immunization Program in July 2014. The study evaluated the long-term impact of the vaccine on hospitalization for all-cause and rotavirus-specific acute gastroenteritis (AGE) and strain epidemiology in Kenya. METHODS: Data on all-cause and rotavirus-specific AGE and strain distribution were derived from an eleven-year hospital-based surveillance of AGE among children aged <5 years at Kiambu County Teaching and Referral Hospital (KCTRH) in Central Kenya between 2009 and 2020. Fecal samples were screened for group A rotavirus using ELISA and genotyped using multiplex semi-nested RT-PCR. Trends in all-cause and rotavirus-related AGE and strain distribution were compared between the pre-vaccine (July 2009-June 2014), early post-vaccine (July 2014-June 2016) and late post-vaccine (February 2019-October 2020) periods. RESULTS: Rotavirus-specific AGE was detected at 27.5% (429/1546, 95% CI: 25.5-30.1%) in the pre-vaccine period; 13.8% (91/658, 95% CI: 11.3-16.6%) in the early post-vaccine period (July 2014-June 2016); and 12.0% (229/1916, 95% CI: 10.6-13.5%) in the late post-vaccine period (February 2019-October 2020). This amounted to a decline of 49.8% (95% CI: 34.6%-63.7%) in rotavirus-specific AGE in the early post-vaccine period and 53.4% (95% CI: 41.5-70.3%) in the late post-vaccine period when compared to the pre-vaccine period. All-cause AGE hospitalizations declined by 40.2% (95% CI: 30.8%-50.2%) and 75.3% (95% CI: 65.9-83.1%) in the early post-vaccine and late post-vaccine periods, respectively, when compared to the pre-vaccine period. G3P [8] was the predominant strain in the late post-vaccine period, replacing G1P[8] which had predominated in the pre-vaccine and early post-vaccine periods. Additionally, we detected considerable proportions of uncommon strains G3P[6] (4.8%) and G12P[6] (3.5%) in the post-vaccine era. CONCLUSION: Rotavirus vaccination has resulted in a significant decline in all-cause and rotavirus-specific AGE, and thus, provides strong evidence for public health policy makers in Kenya to support the sustained use of the rotavirus vaccine in routine immunization. However, the shift in strain dominance and age distribution of rotavirus AGE in the post-vaccine era underscores the need for continued surveillance to assess any possible vaccine-induced selective pressure that could diminish the vaccine effectiveness over time.
引用
- Wandera EA, Kurokawa N, Mutua MM, et al. Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted time-series analysis. Vaccine. 2024. PMID: 39151233. doi:10.1016/j.vaccine.2024.126210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。